Review
doi: 10.1111/j.1749-6632.2012.06757.x.
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond
Affiliations
- PMID: 23050811
- DOI: 10.1111/j.1749-6632.2012.06757.x
Item in Clipboard
Review
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond
Ann N Y Acad Sci.
2012 Oct.
Abstract
Thymosin α1 (Tα1) is an immunomodulatory peptide released by the thymus gland in mammals. It was first described in 1977 as a potential agent for the treatment of immune deficiencies and cancer. Among solid tumors, a number of clinical trials have investigated the activity of Tα1 in melanoma. In particular, a large randomized phase II trial that evaluated the safety and efficacy of combining Tα1 with dacarbazine and interferon alpha in metastatic melanoma patients provided the rationale for further clinical applications. The main findings emerging from clinical trials and that support the therapeutic use of Tα1 in human melanoma are summarized and discussed.
© 2012 New York Academy of Sciences.
Similar articles
-
Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.Melanoma Res. 2000 Apr;10(2):189-92. Melanoma Res. 2000. PMID: 10803720 Clinical Trial. No abstract available.
-
What can we learn from phase II adjuvant trials in melanoma?Br J Cancer. 2000 Jul;83(1):6-7. doi: 10.1054/bjoc.2000.1277. Br J Cancer. 2000. PMID: 10883660 Free PMC article. No abstract available.
-
Historical review on thymosin α1 in oncology: preclinical and clinical experiences.Expert Opin Biol Ther. 2015;15 Suppl 1:S31-9. doi: 10.1517/14712598.2015.1017466. Epub 2015 Jun 22. Expert Opin Biol Ther. 2015. PMID: 26096345 Review.
-
Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.Neoplasma. 2001;48(3):175-81. Neoplasma. 2001. PMID: 11583285
-
Thymosin alpha1. SciClone Pharmaceuticals.Curr Opin Investig Drugs. 2002 May;3(5):698-707. Curr Opin Investig Drugs. 2002. PMID: 12090542 Review.
Cited by
-
A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.PLoS One. 2013 Aug 19;8(8):e72242. doi: 10.1371/journal.pone.0072242. eCollection 2013. PLoS One. 2013. PMID: 23977262 Free PMC article.
-
A Reappraisal of Thymosin Alpha1 in Cancer Therapy.Front Oncol. 2019 Sep 6;9:873. doi: 10.3389/fonc.2019.00873. eCollection 2019. Front Oncol. 2019. PMID: 31555601 Free PMC article. Review.
-
Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.Sci Rep. 2018 Aug 17;8(1):12351. doi: 10.1038/s41598-018-30956-y. Sci Rep. 2018. PMID: 30120362 Free PMC article.
-
Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo.ACS Omega. 2020 Apr 27;5(18):10374-10381. doi: 10.1021/acsomega.0c00220. eCollection 2020 May 12. ACS Omega. 2020. PMID: 32426594 Free PMC article.
-
Effects on tumor growth and immunosuppression of a modified Tα1 peptide along with its circular dichroism spectroscopy data.Data Brief. 2018 Jul 29;20:126-131. doi: 10.1016/j.dib.2018.07.058. eCollection 2018 Oct. Data Brief. 2018. PMID: 30109250 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
